Pharmaceutical innovation as a process of creative destruction

Knowledge Accumulation and Industry Evolution: The Case of Pharma-Biotech

Volumn , Issue , 2006, Pages 21-72

  Lichtenberg, Frank R ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NATIONAL BUREAU OF ECONOMIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84878909504     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511493232.002     Document Type: Chapter

References (36)

1. Conroy, R., R. Harris, and T. Massaro (1992), Assessment of Risk and Capital Costs in the Pharmaceutical Industry, unpublished paper, Darden School of Business, University of Virginia, Charlottesville.
2. Cornett, M.M., and H. Tehranian (1992), “Changes in corporate performance associated with bank acquisitions,” Journal of Financial Economics, 31 (April), 211–34.
3. Cutler, D., M. McClellan, J. Newhouse, and D. Remler (1998), “Are medical prices declining?,” Quarterly Journal of Economics, 113 (4), 991–1024.
4. Dornbusch, R., and S. Fischer (1994), Macroeconomics, 6th edn., McGraw- Hill, New York.
5. Dustan, H. P., E. J. Roccella, and H. H. Garrison (1996), “Controlling hypertension: a research success story,” Archives of Internal Medicine, 56 (23 September), 1926–35.
6. Eisner, R. (1978), Factors in Business Investment, Ballinger (for the National Bureau of Economic Research), Cambridge, MA.
7. Ellison, S., and W. Mullin (1997), Gradual Incorporation of Information into Stock Prices: Empirical Strategies, Working Paper no. 6218, National Bureau of Economic Research, Cambridge, MA.
8. F&S Index, United States Annual (various years), Information Access Co., Foster City, CA.
9. Grabowski, H. (1968), “The determinants of industrial research and development: a study of the chemical, drug, and petroleum industries,” Journal of Political Economy, 76, 292–306.
10. Grabowski, H. G., and J. Vernon (1981), “The determinants of research and development: expenditures in the pharmaceutical industry,” in R. Helms (ed.), Drugs and Health, American Enterprise Institute, Washington, DC.
11. Griliches, Z., and F. Lichtenberg (1984), “R&D and productivity at the industry level: is there still a relationship?,” in Z. Griliches (ed.), R&D, Patents, and Productivity, University of Chicago Press, Chicago, 465–96.
12. Hall, R., and J. Taylor (1991), Macroeconomics, 3rd edn., Norton, New York.
13. Hassett, K., and R. G. Hubbard (1996), Tax Policy and Investment, unpublished paper, Federal Reserve Board of Governors and Columbia Business School, New York.
14. Hayashi, F. (1982), “Tobin’s marginal q and average q: a neoclassical interpretation,” Econometrica, 50, 213–24.
15. Healy, P., K. Palepu, and R. Ruback (1992), “Does corporate performance improve after mergers?,” Journal of Financial Economics, 31 (April), 135–75.
16. Jaffe, A., and K. Palmer (1997), “Environmental regulation and innovation: a panel data study,” Review of Economics and Statistics, 79 (4), 610–19.
17. Jensen, E. (1987), “Research expenditures and the discovery of new drugs,” Journal of Industrial Economics, 36, 83–95.
18. Jensen, E. (1990), The Determinants of Research and Development Expenditures in the Ethical Pharmaceutical Industry, unpublished paper, Hamilton College, Clinton, NY.
19. Kaplan, S., and R. Ruback (1995), “The valuation of cash flow forecasts: an empirical analysis,” Journal of Finance 50 (September), 1059–93.
20. Keynes, J. M. (1936), The General Theory of Employment, Interest and Money, Macmillan, London.
21. Lichtenberg, F. (1996), “Do (more and better) drugs keep people out of hospitals?,” American Economic Review, 86, 384–8.
22. Lichtenberg, F. (1997), “The allocation of publicly funded biomedical research,” in E. Bernat and D. Cutler (eds.), Medical Care Output and Productivity, Studies in Income and Wealth no. 62, University of Chicago Press, Chicago, 565–89.
23. Lichtenberg, F. (2000), “Comment on paper by Skinner and Wennberg,” in D. Cutler (ed.), The Changing Hospital Industry: Comparing Not-For-Profit and For-Profit Institutions, University of Chicago Press, Chicago.
24. Lichtenberg, F. and D. Siegel (1991), “The impact of R&D investment on productivity: new evidence using linked R&D–LRD data,” Economic Inquiry, 29 (April), 203–28.
25. Malkiel, B. (1990), A Random Walk Down Wall Street, 5th edn., Norton, New York.
26. National Center for Health Statistics (2004), Health, United States, 2004: With Chartbook on Trends in the Health of Americans, available at http://www.cdc.gov/nchs/data/hus/hus04.pdf.
27. National Science Board (1993), Science and Engineering Indicators – 1993, Government Publishing Office, Washington, DC.
28. New York Times (1995), “Benefit to healthy men is seen from cholesterolcutting drug,” 16 November, A1.
29. New York Times (1998), “AIDS deaths drop 48% in New York,” 3 February, A1.
30. Pharmaceutical Research and Manufacturers Association (1997), PhRMA Annual Survey, available at http://www.phrma.org/facts/data/R&D.html.
31. Rogerson, W. (1989), “Profit regulation of defense contractors and prizes for innovation,” Journal of Political Economy, 97, 1284–1305.
32. Schumpeter, J. A. (1942), Capitalism, Socialism, and Democracy, Harper and Brothers, New York.
33. Skinner, J. S., and J. E. Wennberg (2000), “How much is enough? Efficiency and Medicare spending in the last six months of life,” in D. Cutler (ed.), The Changing Hospital Industry: Comparing Not-For-Profit and For-Profit Institutions, University of Chicago Press, Chicago, 169–93.
34. Tobin, J. (1969), “A general equilibrium approach to monetary theory,” Journal of Money, Credit, and Banking, 1 (February), 15–29.
35. Toole, A. (1998), The Impact of Public Basic Research on Industrial Innovation: Evidence from the Pharmaceutical Industry, Discussion Paper no. 98–6, Stanford Institute for Economic Policy Research, Stanford University, CA.
36. Viscusi, W. K. (1993), “The value of risks to life and health,” Journal of Economic Literature, 31, 1912–46.